Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English
  • Bengali
  • Hindi

Education

Medical School

Medical College and Hospital, Kolkata / Calcutta Medical College

2004, Kolkata, India

Residency

SUNY Downstate College of Medicine

2008, Brooklyn, NY

Graduate School

MS, Clinical and Translational Science

Mayo Clinic School of Graduate Medical Education

2011, Rochester, MN

Fellowship

Pediatric Hematology/Oncology

Mayo Clinic

2011, Rochester, MN

Fellowship

Pediatric Thrombosis/Hemostasis

The Hospital for Sick Children

2013, Toronto, Ontario, Canada

Certifications

  • American Board of Pediatrics (General)
  • American Board of Pediatrics (Hematology-Oncology)

Professional History

Dr. Riten Kumar is the clinical director of the Thrombosis and Anticoagulation Program at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dr. Kumar received his medical degree from Calcutta Medical College in India. He then completed his pediatric residency at State University of New York. He finished his pediatric hematology-oncology fellowship at the Mayo Clinic in Minnesota while also earning his Master's in Clinical and Translational Science from the Mayo School of Graduate Medical Education. In 2013, he completed a second fellowship in Pediatric Thrombosis and Hemostasis at the Hospital for Sick Children, University of Toronto in Canada.

Publications

  1. American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients. Blood Adv. 2025 May 27; 9(10):2587-2636. View Abstract

  2. Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial. Lancet Haematol. 2025 Apr 10. View Abstract

  3. The Functional Characterization of Venous Thromboembolic Disease (FUVID) study: rationale, design, and methods of a prospective, observational, multicenter study to evaluate mechanisms of exercise intolerance and dyspnea following pediatric pulmonary embolism. Res Pract Thromb Haemost. 2025 Jan; 9(1):102669. View Abstract

  4. Pancreatitis-associated thrombotic microangiopathic hematolytic anemia with thrombocytopenia in a child. Blood. 2024 Nov 21; 144(21):2270. View Abstract

  5. Trends in the Diagnosis of Pediatric Venous Thromboembolism and Arterial Ischemic Stroke during the COVID-19 Pandemic: An Administrative Database Study. J Pediatr. 2025 Jan; 276:114328. View Abstract

  6. Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study. Pediatr Blood Cancer. 2024 Nov; 71(11):e31284. View Abstract

  7. A novel heterozygous frameshift c.277del p.Thr93Leufs*21 mutation in SERPINC1 associated with type 1 antithrombin deficiency. Pediatr Blood Cancer. 2024 Jun; 71(6):e30986. View Abstract

  8. Improving Anticoagulation Care for Pediatric Oncology Patients: A Quality Improvement Initiative. Pediatr Qual Saf. 2024 Jan-Feb; 9(1):e720. View Abstract

  9. Efficacy and safety of antithrombin supplementation in neonates and infants on a continuous heparin infusion. Res Pract Thromb Haemost. 2024 Jan; 8(1):102336. View Abstract

  10. Clinical decision support to enhance venous thromboembolism pharmacoprophylaxis prescribing for pediatric inpatients with COVID-19. Pediatr Blood Cancer. 2024 Mar; 71(3):e30843. View Abstract

  11. Thrombotic complications in children with Coronavirus disease 2019 and Multisystem Inflammatory Syndrome of Childhood. J Thromb Haemost. 2023 09; 21(9):2313-2326. View Abstract

  12. Impact of SERPINC1 mutation on thrombotic phenotype in children with congenital antithrombin deficiency-first analysis of the International Society on Thrombosis and Haemostasis pediatric antithrombin deficiency database and biorepository. J Thromb Haemost. 2023 05; 21(5):1248-1257. View Abstract

  13. Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium. Res Pract Thromb Haemost. 2022 Oct; 6(7):e12793. View Abstract

  14. Improving guideline-concordant thromboprophylaxis prescribing for children admitted to hospital with COVID-19. Pediatr Blood Cancer. 2023 02; 70(2):e30112. View Abstract

  15. Hemostatic and Thrombotic Considerations in the Diagnosis and Management of Childhood Arterial Ischemic Stroke: A Narrative Review. Semin Pediatr Neurol. 2022 10; 43:101003. View Abstract

  16. High Rate of Venous Thromboembolism in Severe Pediatric Intestinal Failure. J Pediatr. 2023 02; 253:152-157. View Abstract

  17. Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 09 08; 140(10):1156-1166. View Abstract

  18. Appendix to the Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions: Pediatric Considerations. J Vasc Interv Radiol. 2022 11; 33(11):1424-1431. View Abstract

  19. Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress. Res Pract Thromb Haemost. 2022 Jul; 6(5):e12747. View Abstract

  20. Venous thromboembolism in pediatric patients with sickle cell disease: A north American survey on experience and management approaches of pediatric hematologists. Thromb Res. 2022 Mar; 211:133-139. View Abstract

  21. A Review of Venous Thromboembolism Risk Assessment and Prophylaxis in Plastic Surgery. Plast Reconstr Surg. 2022 Jan 01; 149(1):121e-129e. View Abstract

  22. Venous thoracic outlet syndrome and Paget-Schroetter syndrome. Semin Pediatr Surg. 2021 Dec; 30(6):151125. View Abstract

  23. Acute Management of High-Risk and Intermediate-Risk Pulmonary Embolism in Children: A Review. Chest. 2022 03; 161(3):791-802. View Abstract

  24. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood. 2021 07 15; 138(2):190-198. View Abstract

  25. Bleeding Severity and Phenotype in 22q11.2 Deletion Syndrome-A Cross-Sectional Investigation. J Pediatr. 2021 Aug; 235:220-225. View Abstract

  26. Unfractionated heparin using actual body weight without dose capping in obese pediatric patients-Subgroup analysis from an observational cohort study. Pediatr Blood Cancer. 2021 03; 68(3):e28872. View Abstract

  27. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv. 2020 12 22; 4(24):6250-6258. View Abstract

  28. Venous thromboembolism in children with central nervous system tumors: Comparison of an institutional cohort to a national administrative database. Pediatr Blood Cancer. 2021 03; 68(3):e28846. View Abstract

  29. Fibrinogen Columbus III: A novel c.963del frameshift mutation in the FGG gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatr Blood Cancer. 2021 03; 68(3):e28713. View Abstract

  30. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020 07; 18(7):1672-1685. View Abstract

  31. Catheter-directed thrombolysis for submassive pulmonary embolism in children: A case series. Pediatr Blood Cancer. 2020 04; 67(4):e28144. View Abstract

  32. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020 Jan; 7(1):e18-e27. View Abstract

  33. Popliteal Artery Entrapment Syndrome Presenting with Critical Limb Ischemia in an Adolescent. J Pediatr. 2020 02; 217:215-215.e1. View Abstract

  34. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019 Oct; 6(10):e500-e509. View Abstract

  35. Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male. Pediatr Blood Cancer. 2019 09; 66(9):e27832. View Abstract

  36. Valproic Acid-Induced Coagulopathy. Pediatr Neurol. 2019 09; 98:25-30. View Abstract

  37. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. J Pediatr. 2019 06; 209:212-219.e1. View Abstract

  38. Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatr Blood Cancer. 2019 04; 66(4):e27588. View Abstract

  39. Treatment-Related Outcomes in Paget-Schroetter Syndrome-A Cross-Sectional Investigation. J Pediatr. 2019 04; 207:226-232.e1. View Abstract

  40. Klinefelter syndrome as a risk factor for recurrent deep vein thrombosis in an adolescent male: Significance of a thorough physical examination. Pediatr Blood Cancer. 2018 08; 65(8):e27080. View Abstract

  41. Venous Thromboembolism in Children with Sickle Cell Disease: A Retrospective Cohort Study. J Pediatr. 2018 06; 197:186-190.e1. View Abstract

  42. Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study. Blood Adv. 2018 02 13; 2(3):285-291. View Abstract

  43. Risk Factors for Neonatal Venous and Arterial Thromboembolism in the Neonatal Intensive Care Unit-A Case Control Study. J Pediatr. 2018 04; 195:28-32. View Abstract

  44. Mesoaortic compression of a left-sided inferior vena-cava presenting as recurrent pulmonary embolism in a child-a novel anatomic thrombophilia? Pediatr Blood Cancer. 2018 06; 65(6):e26986. View Abstract

  45. Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. Biol Blood Marrow Transplant. 2018 02; 24(2):337-342. View Abstract

  46. Activated Partial Thromboplastin Time versus Anti-Factor Xa Levels for Monitoring Unfractionated Heparin Therapy in Children: An Institutional Experience. J Pediatr Hematol Oncol. 2017 10; 39(7):576-577. View Abstract

  47. Thrombosis of the Abdominal Veins in Childhood. Front Pediatr. 2017; 5:188. View Abstract

  48. Inferior vena cava atresia predisposing to acute lower extremity deep vein thrombosis in children: A descriptive dual-center study. Pediatr Blood Cancer. 2018 Feb; 65(2). View Abstract

  49. Arterial Ischemic Stroke in Children and Young Adults. Continuum (Minneap Minn). 2017 02; 23(1, Cerebrovascular Disease):158-180. View Abstract

  50. Thrombocytopenia Pitfalls: Misdiagnosing Type 2B von Willebrand Disease as Ethylenediaminetetraacetic Acid-Dependent Pseudothrombocytopenia. J Pediatr. 2016 Aug; 175:238-238.e1. View Abstract

  51. Molecular structural analysis of a novel and de-novo mutation in the SERPINC1 gene associated with type 1 antithrombin deficiency. Br J Haematol. 2017 05; 177(4):654-656. View Abstract

  52. Impact of aerobic exercise on haemostatic indices in paediatric patients with haemophilia. Thromb Haemost. 2016 06 02; 115(6):1120-8. View Abstract

  53. Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy. Semin Thromb Hemost. 2016 Feb; 42(1):18-29. View Abstract

  54. aPTT in children receiving UFH: time for a change? Blood. 2015 Oct 29; 126(18):2075-6. View Abstract

  55. c.1058C>T variant in the SERPINC1 gene is pathogenic for antithrombin deficiency. Br J Haematol. 2015 Jul; 170(1):123-5. View Abstract

  56. Prevalence and risk factors for post thrombotic syndrome after deep vein thrombosis in children: a cohort study. Thromb Res. 2015 Feb; 135(2):347-51. View Abstract

  57. Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol. 2014 Dec; 37(6):635-41. View Abstract

  58. Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study. Br J Haematol. 2014 Jul; 166(1):130-9. View Abstract

  59. Health-related quality of life in children and young adults with post-thrombotic syndrome: results from a cross-sectional study. Pediatr Blood Cancer. 2014 Mar; 61(3):546-51. View Abstract

  60. Inherited abnormalities of coagulation: hemophilia, von Willebrand disease, and beyond. Pediatr Clin North Am. 2013 Dec; 60(6):1419-41. View Abstract

  61. Congenital thrombocytopenia: clinical manifestations, laboratory abnormalities, and molecular defects of a heterogeneous group of conditions. Hematol Oncol Clin North Am. 2013 Jun; 27(3):465-94. View Abstract

  62. Consequences of delayed therapy for sports-related bleeds in patients with mild-to-moderate haemophilia and type 3 von Willebrand's disease not on prophylaxis. Haemophilia. 2013 Jul; 19(4):e264-7. View Abstract

  63. A novel mutation in the SerpinC1 gene presenting as unprovoked neonatal cerebral sinus venous thrombosis in a kindred. Pediatr Blood Cancer. 2013 Jan; 60(1):133-6. View Abstract

  64. Treatment of Hodgkin's lymphoma in a patient with type III von Willebrand's disease. Haemophilia. 2012 Sep; 18(5):e378-9. View Abstract

  65. Pretransplant conditioning with Campath-1H (alemtuzumab) in pediatric matched unrelated hematopoietic stem cell transplants: an institutional experience. J Pediatr Hematol Oncol. 2012 Mar; 34(2):96-100. View Abstract

  66. Development and initial validation of a questionnaire to diagnose the presence and severity of post-thrombotic syndrome in children. Pediatr Blood Cancer. 2012 Apr; 58(4):643-4. View Abstract

  67. Postradiation dermatofibrosarcoma protuberans in a patient with Wilms tumor. J Pediatr Hematol Oncol. 2011 Dec; 33(8):635-6. View Abstract

  68. Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma. Pediatr Blood Cancer. 2011 Aug; 57(2):317-20. View Abstract

  69. Pelvic pseudotumor and pseudoaneurysm in a pediatric patient with moderate hemophilia B: successful management with arterial embolization and surgical excision. Pediatr Blood Cancer. 2011 Mar; 56(3):484-7. View Abstract

  70. Pediatric histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A. Pediatr Blood Cancer. 2011 Feb; 56(2):307-10. View Abstract

  71. Successful treatment of a child with T/myeloid acute bilineal leukemia associated with TLX3/BCL11B fusion and 9q deletion. Pediatr Blood Cancer. 2011 Mar; 56(3):467-9. View Abstract

  72. A short course of prednisone in the management of acute chest syndrome of sickle cell disease. J Pediatr Hematol Oncol. 2010 Apr; 32(3):e91-4. View Abstract

  73. A severe case of acute generalized exanthematous pustulosis (AGEP) in a child after the administration of amoxicillin-clavulanic acid: brief report. Pediatr Dermatol. 2009 Sep-Oct; 26(5):623-5. View Abstract

  74. Non-catheter related internal jugular vein thrombosis in a patient with severe haemophilia A. Haemophilia. 2009 Nov; 15(6):1339-40. View Abstract
BESbswy